---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-099123"
form_type: "8-K"
ticker: "KR"
cik: "0000056873"
company_name: "KROGER CO"
filed_at: "2023-09-08T23:59:59+00:00"
generated_at: "2026-06-10T22:24:02.485046+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Kroger Q2 adj EPS $0.96, $1.4B opioid charge, $1.9B C&S divestiture

## Summary
- Q2 sales $33.9B (-2% YoY); ID sales +1.0%; operating loss ($479M) incl $1.4B opioid charge; adj EPS $0.96 vs $0.90 last year.
- Opioid settlement: up to $1.2B to states/subdivisions, $36M to tribes over 11 yrs, $177M fees; after-tax NPV ~$870M; charge in Q2.
- Divestiture: definitive agreement with C&S for 413 stores, 8 DCs, 2 offices, 5 private labels; $1.9B cash; option for up to 237 more stores.
- FY2023 guidance reaffirmed: adj EPS $4.45-$4.60, adj FIFO operating profit $5.0-$5.2B, capex $3.4-$3.6B.
- Net total debt to adj EBITDA ratio 1.31 (target 2.30-2.50); merger on track for early 2024 subject to FTC clearance.

## SEC filing metadata
- accession: 0001104659-23-099123
- form_type: 8-K
- ticker: KR
- cik: 0000056873
- company_name: KROGER CO
- filed_at: 2023-09-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/0001104659-23-099123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/tm2325655d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-099123
- JSON: https://secwatch.observer/filing/0001104659-23-099123.json
- Plain text: https://secwatch.observer/filing/0001104659-23-099123.txt

## Key facts
- Earnings Releases
  KROGER CO reported second quarter 2023 results: revenue $33.9 billion, EPS $(0.25). Guidance reaffirmed.
  - Period: second quarter 2023
  - Revenue: $33.9 billion
  - EPS: $(0.25)
  - Guidance: reaffirmed
  - Result: reported results
  source text: on operating profit was slightly positive. ** Includes a $1.4 billion ($1.54 loss per share) charge related to nationwide opioid settlement framework. Total company sales were $33.9 billion in the second quarter, compared to $34.6 billion for the same period last year. Excluding fuel, sales increased 1.1% compared to the same period last year. Gross margin was 21.8%
  evidence_url: https://www.sec.gov/Archives/edgar/data/56873/000110465923099123/0001104659-23-099123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.